Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...

Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in ...

The trial, conducted and funded by GenFleet Therapeutics (Shanghai), Inc. (“Genfleet”), was an open-label single-arm multicenter Phase 2a study in China evaluating SLS009 in combination with ...

Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients - - Median Overall ...

Sellas Life Sciences (SLS) announced data from Phase 2a trial of SLS009 – tambiciclib -, a highly selective CDK9 inhibitor, in ...

Interestingly, genetic analysis indicated that the patient who achieved complete response had MYC amplification and TP53 mutations, suggesting that CDK9 inhibition with SLS009 may overcome drug ...

SELLAS Life Sciences Group (NASDAQ:SLS) announced on Thursday promising mid-stage trial results for SLS009, a highly ...

The 96-square-kilometer Tosso Creek Project is located in southern Suriname, approximately 180 km south of the capital city, ...

Pre-Market: 9:25:13 a.m. EST ...